Annals of Surgical Oncology, Vol 6, Issue 4 405-412, Copyright © 1999 by Society of Surgical Oncology

ARTICLES

Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan

B. C. Vrouenraets, B. B. Kroon, A. C. Ogilvie, A. N. van Geel, O. E. Nieweg, A. J. Swaak and A. M. Eggermont
Department of Surgery, The Netherlands Cancer Institute (Antoni van Leeuwenhoek ziekenhuis), Amsterdam.

BACKGROUND: Severe systemic toxicity and hemodynamic changes after isolated limb perfusion (ILP) with tumor necrosis factor-alpha (TNF-alpha) and melphalan, with or without interferon-gamma, have been reported in several series. We studied whether these side effects could be precluded by preventing leakage from the isolated circuit into the systemic circulation. METHODS: Clinical and pharmacokinetic data for 20 consecutive patients with recurrent melanoma of the limbs who were treated by ILP with TNF-alpha (3-4 mg) and melphalan, with or without interferon-gamma, were studied. Leakage rates and TNF-alpha levels were determined during and after ILP and were correlated with systemic toxicity and hemodynamic changes. RESULTS: Only two patients experienced leaks (2% and 13%) during ILP. For 18 patients without leakage, the mean peak systemic TNF-alpha level was 2.8 ng/ml at 10 minutes after ILP. After leakage, the peak systemic TNF-alpha levels were 31.9 and 88.3 ng/ml at 5 minutes. Toxicity was mild and consisted mainly of fever (n = 17) and nausea/vomiting (n = 19) during the first day after ILP. Some patients developed tachycardia (n = 6), hypotension (n = 3; responding immediately to fluid challenge), a decrease in the WBC count (n = 3; grade I) or thrombocyte count (n = 11; grade I/II, no hemorrhage or therapeutic intervention), or hepatotoxicity [cytolysis (n = 15; 14 grade I/II and 1 grade IV) or hyperbilirubinemia (n = 7; grade I/II, all resolving spontaneously)]. Patients with tachycardia or hepatotoxicity exhibited significantly higher TNF-alpha levels after ILP, compared with other patients. CONCLUSIONS: Systemic toxicity after ILP with TNF-alpha is minimal and does not differ from that after ILP with melphalan alone when leakage is adequately controlled.

This article has been cited by other articles:

				P. Hohenberger and W. M. Wysocki Neoadjuvant Treatment of Locally Advanced Soft Tissue Sarcoma of the Limbs: Which Treatment to Choose? Oncologist, February 1, 2008; 13(2): 175 - 186. [Abstract] [Full Text] [PDF]

				D. J. Grunhagen, B. van Etten, F. Brunstein, W. J. Graveland, A. N. van Geel, J. H. W. de Wilt, and A. M. M. Eggermont Efficacy of Repeat Isolated Limb Perfusions With Tumor Necrosis Factor {alpha} and Melphalan for Multiple In-Transit Metastases in Patients with Prior Isolated Limb Perfusion Failure Ann. Surg. Oncol., August 1, 2005; 12(8): 609 - 615. [Abstract] [Full Text] [PDF]

				S. Bonvalot, A. Laplanche, F. Lejeune, E. Stoeckle, C. Le Pechoux, D. Vanel, P. Terrier, J. Lumbroso, M. Ricard, G. Antoni, et al. Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-{alpha} be better? Ann. Onc., July 1, 2005; 16(7): 1061 - 1068. [Abstract] [Full Text] [PDF]

				C. R. Rossi, S. Mocellin, P. Pilati, M. Foletto, L. Campana, L. Quintieri, G. L. De Salvo, and M. Lise Hyperthermic Isolated Perfusion With Low-Dose Tumor Necrosis Factor {alpha} and Doxorubicin for the Treatment of Limb-Threatening Soft Tissue Sarcomas Ann. Surg. Oncol., May 1, 2005; 12(5): 398 - 405. [Abstract] [Full Text] [PDF]

				T. E. Lans, D. J. Grunhagen, J. H. W. de Wilt, A. N. van Geel, and A. M. M. Eggermont Isolated Limb Perfusions With Tumor Necrosis Factor and Melphalan for Locally Recurrent Soft Tissue Sarcoma in Previously Irradiated Limbs Ann. Surg. Oncol., May 1, 2005; 12(5): 406 - 411. [Abstract] [Full Text] [PDF]

				P. Hohenberger, E. Latz, C. Kettelhack, A.-H. Rezaei, R. Schumann, and P. M. Schlag Pentoxifyllin Attenuates the Systemic Inflammatory Response Induced During Isolated Limb Perfusion With Recombinant Human Tumor Necrosis Factor-{alpha} and Melphalan Ann. Surg. Oncol., June 1, 2003; 10(5): 562 - 568. [Abstract] [Full Text] [PDF]

				B. van Etten, A. N. van Geel, J. H. W. de Wilt, and A. M. M. Eggermont Fifty Tumor Necrosis Factor-Based Isolated Limb Perfusions for Limb Salvage in Patients Older Than 75 Years With Limb-Threatening Soft Tissue Sarcomas and Other Extremity Tumors Ann. Surg. Oncol., January 1, 2003; 10(1): 32 - 37. [Abstract] [Full Text] [PDF]

				E.M. Noorda, B.C. Vrouenraets, O.E. Nieweg, A.N. van Geel, A.M. M. Eggermont, and B.B. R. Kroon Safety and Efficacy of Isolated Limb Perfusion in Elderly Melanoma Patients Ann. Surg. Oncol., December 1, 2002; 9(10): 968 - 974. [Abstract] [Full Text] [PDF]

				R. J. van Ginkel, P. C. Limburg, D. A. Piers, H. S. Koops, and H. J. Hoekstra Value of Continuous Leakage Monitoring With Radioactive Iodine-131-Labeled Human Serum Albumin During Hyperthermic Isolated Limb Perfusion With Tumor Necrosis Factor-{alpha} and Melphalan Ann. Surg. Oncol., May 1, 2002; 9(4): 355 - 363. [Abstract] [Full Text] [PDF]